Archival Report

Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse


ABSTRACT
BACKGROUND: Standard guidelines recommend selective serotonin reuptake inhibitors as first-line antidepressants for adults with major depressive disorder, but success is limited and patients who fail to benefit are often switched to non–selective serotonin reuptake inhibitor agents. This study investigated whether brain- and behavior-based markers of reward processing might be associated with response to bupropion after sertraline nonresponse.

METHODS: In a two-stage, double-blinded clinical trial, 296 participants were randomized to receive 8 weeks of sertraline or placebo in stage 1. Individuals who responded continued on another 8-week course of the same intervention in stage 2, while sertraline and placebo nonresponders crossed over to bupropion and sertraline, respectively. Data from 241 participants were analyzed. The stage 2 sample comprised 87 patients with major depressive disorder who switched medication with sertraline in stage 1 served as an independent replication sample. The probabilistic reward task and resting-state functional magnetic resonance imaging were administered at baseline.

RESULTS: Greater pretreatment reward sensitivity and higher resting-state functional connectivity between bilateral nucleus accumbens and rostral anterior cingulate cortex were associated with positive response to bupropion but not sertraline. Null findings for sertraline were replicated in the stage 1 sample.

CONCLUSIONS: Pretreatment reward sensitivity and frontostriatal connectivity may identify patients likely to benefit from bupropion following selective serotonin reuptake inhibitor failures. Results call for a prospective replication based on these biomarkers to advance clinical care.

Keywords: Antidepressant response, Biomarkers, Bupropion, Frontostriatal connectivity, Reward sensitivity, Sertraline

https://doi.org/10.1016/j.biopsych.2020.04.009

Major depressive disorder (MDD) is a debilitating and recurrent condition associated with substantial personal socioeconomic costs (1,2). Despite significant efforts, treatment of MDD remains imprecise and involves trial and error to determine the most effective approach. Findings from the STAR*D trial revealed that only about half of individuals with MDD responded (i.e., exhibited ≥50% reduction in depressive symptoms) to the selective serotonin reuptake inhibitor (SSRI) citalopram (3), and more than one third failed to respond to two or more antidepressants (4,5). The situation is even worse in primary care, where only ~30% respond to first-line antidepressants (6). To exacerbate these issues, it takes at least 4 weeks to evaluate the efficacy of an antidepressant. This can lead to lengthy treatment trials that are insufficient and unnecessary, thereby increasing patient morbidity, drop-outs, and suicide risk.

This limited success partially stems from the fact that treatment selection is not based on identification of the underlying biomarker abnormality that reflects pathophysiology (7,8). Hence, some individuals with depression may benefit from SSRIs, while others might be better suited to other classes of medication. Identifying objective markers that reliably predict responses to different classes of antidepressants would critically help clinicians decide whether a particular medication might be suitable for the patient.
Functional magnetic resonance imaging (fMRI) studies have reported that pretreatment activation to emotional stimuli in the anterior cingulate cortex (9) and amygdala (10), as well as to nonemotional stimuli in the frontocingulate (11–13) and parietal (14) regions, was associated with greater improvements in depressive symptoms on SSRIs (15). Moreover, a recent study found that connectivity within the cognitive control network during a response inhibition task differentially predicts response to sertraline and venlafaxine (16). Converging evidence from resting-state studies also suggests that increased pretreatment activity in the rostral anterior cingulate cortex (rACC) predicts treatment response across a variety of interventions, including multiple antidepressants (17,18). In addition, executive dysfunction, psychomotor slowing, and impaired memory at baseline have been linked to poor clinical outcome on various medications (19–31), although lack of replicability exists (32–34). Finally, higher pretreatment levels of C-reactive protein (35), interleukin-17 (36), and platelet-derived growth factor (37) were associated with better improvement in depressive severity when treated with a combination of bupropion and escitalopram.

Despite these promising findings, two important gaps exist in prior literature. First, to the best of our knowledge, no study has examined brain–behavior factors associated with response to second-line antidepressants, especially after failing a full course of an SSRI. Current guidelines recommend SSRIs as first-line antidepressant treatments (38), but response rates are modest, and patients with depression who fail to benefit are often switched to non-SSRI agents (38–41). Previous studies have never explored whether pretreatment biological and behavioral markers can differentiate between responders to a second antidepressant, after failure on a pharmacologically distinct class of medication, and nonresponders resistant to both arms of treatment.

Second, alterations in the reward processing circuitry—modulated by dopamine and centered on the ventral striatum (VS) and medial prefrontal cortex—have been implicated in MDD (15,17,42–53). Emerging research also suggests that an impaired ability to respond to rewards is associated with anhedonia, a core feature of MDD (45,54,55). However, few studies have examined the degree to which markers of reward processing predict antidepressant response. A small open-label study in adolescents showed that pretreatment VS activity during reward anticipation was not linked to the severity of depressive symptoms after cognitive behavioral therapy or cognitive behavior therapy plus SSRI (56). The placebo-controlled Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial in unmedicated individuals with MDD also reported that pretreatment reward responsiveness did not associate with treatment outcome to the SSRI sertraline (57); however, better response to sertraline was linked to more abnormal VS temporal dynamics during a reward task (58). Given the key role of dopamine in reward processing (59,60), these previous findings raise the question of whether reward markers might be associated with response to dopaminergic (but not serotoninergic-based) antidepressants, and if they are, which ones.

The current study sought to address the two aforementioned gaps in the context of the two-stage, double-blinded EMBARC study (61). A probabilistic reward task (PRT) was a priori selected to investigate response to bupropion, a noradrenaline/dopamine reuptake inhibitor. PRT reward responsiveness and resting-state fMRI data were collected at baseline of an 8-week clinical trial, where outpatients with recurrent and nonpsychotic MDD were randomized to receive sertraline or placebo (stage 1). Participants who achieved satisfactory response at the end of stage 1 continued on another 8-week course of the same intervention, while nonresponders were crossed over under double-blinded conditions. Thus, sertraline nonresponders received bupropion and placebo nonresponders received sertraline in stage 2. For comparison, baseline PRT and resting-state fMRI data were also collected from healthy control subjects.

Our goal was to examine whether neural and behavioral markers of reward processing were associated with response to secondary treatment by bupropion (after nonresponse to sertraline) and sertraline (after nonresponse to placebo). Based on the premise that dopaminergic blunting plays an important role in anhedonic phenotypes (62,63), we hypothesized that patients with more impaired reward responsiveness and resting-state functional connectivity (RSFC) within the reward circuit would disproportionally benefit from a dopaminergic antidepressant (bupropion) after failure to respond to an SSRI (sertraline), distinguishing them from nonresponders who were resistant to both classes of medication. In addition, we did not expect these reward markers to differentiate response to sertraline.

METHODS AND MATERIALS

Participants

The EMBARC trial recruited outpatients with MDD and healthy volunteers from Columbia University (New York), Massachusetts General Hospital (Boston), University of Texas Southwestern Medical Center (Dallas), and University of Michigan (Ann Arbor) between July 29, 2011, and December 15, 2015, after approval by the institutional review board of each site. All enrolled participants provided written informed consent and were 18 to 65 years old. Details of the study design and a list of inclusion/exclusion criteria can be found in Trivedi et al. (61).

Probabilistic Reward Task

The PRT assessed the ability to modulate behavior based on rewards received (59). On every trial, participants viewed one of two briefly presented (100 ms) and perceptually similar (11.5- vs. 13.0-mm lines) stimuli. Participants needed to indicate which stimulus was shown via a button press. Importantly, and unbeknownst to participants, a 3:1 reinforcement ratio was adopted such that correct responses to one stimulus were rewarded three times more frequently than to the other—a manipulation that induces a response bias (i.e., preference for the more frequently rewarded stimulus). Performance was analyzed in terms of response bias (objective measure of reward responsiveness) and discriminability (ability to distinguish between the stimuli). See Supplemental Methods for details.

Computational Modeling

To dissociate the influence of reward sensitivity (i.e., immediate behavioral impact of rewards) and learning rate (i.e., ability...
Reward Biomarkers of Response to Bupropion

to accumulate and learn from rewards over time) on PRT performance, 4 different models were fitted to participants’ trial-by-trial data (64). Following previously established procedures, we used expectation maximization to derive group priors and used individual Laplace approximation of posterior distributions for parameter estimations for each participant. Models were compared using integrated group-level Bayesian information criterion factors. See Supplemental Methods for details.

Region of Interest

Analyses focused on voxelwise RSFC of a seed region of the bilateral nucleus accumbens (NACC), defined using the Automated Anatomical Labeling atlas (65). The NACC was selected because significant evidence has implicated this region as a key area in different aspects of reward processing (66), including reinforcement learning and reward anticipation (66–71), as well as acquisition and development of reward-based behavior (72–74). Moreover, the VS (which includes the NACC) contains widespread afferent connections to cortical regions that mediate reward processes such as the ventromedial prefrontal, orbitofrontal, and anterior cingulate cortices (60,75). Pharmacological challenge studies provide further support, showing that administering drugs that enhance ventrostriatal signaling improves reward learning, while disrupting phasic dopamine release causes an impairment (50,59). Collectively, these findings motivated us to focus on the NACC region of interest in the RSFC analyses.

MRI Acquisition and Analyses

Acquisition, Preprocessing, Head Motion and Artifact Detection, and Denoising. See Supplemental Methods.

First-Level Analysis. Fisher’s z-transformed Pearson’s correlation coefficient was computed between time course of the NACC seed and that of all other voxels. For each participant, this yielded a beta map containing, at each voxel, an estimate of the correlation in activity between the NACC seed and that voxel over the scan duration.

Group-Level Analyses. Group-level analyses were performed by entering first-level maps into a whole-brain analysis to test for an interaction between medication type (sertraline vs. bupropion) and response status (responders vs. nonresponders) in voxelwise NACC. The contrast was sertraline responder (−1), sertraline nonresponder (+1), bupropion responder (+1), bupropion nonresponder (−1). Scanning site and motion variables were included as covariates, but the inclusion of these covariates did not affect the significance of RSFC effects. Group-level effects were considered significant if they exceeded a peak amplitude of $p < .001$ (two-sided), cluster corrected to false discovery rate of $p < .05$.

Post Hoc RSFC Analyses. To interrogate the nature of group differences underlying significant interaction effects, RSFC estimates were extracted from clusters identified by voxelwise analysis using REX (https://www.nitrc.org/projects/rex) (76). Then, RSFC in clusters of effect was compared between sertraline responders and nonresponders and between bupropion responders and nonresponders using independent t tests and effect size comparison. In addition, post hoc voxelwise analyses were performed comparing bilateral NACC RSFC of responders vs. nonresponders within each medication group.

Clinical Measure

The 17-item Hamilton Rating Scale for Depression (HAM-D) (77) was administered at baseline, stage 1 (weeks 1, 2, 3, 4, 6, and 8), and stage 2 (weeks 9, 10, 12, and 16). Here, patients were defined as responders for each stage if they completed at least 4 weeks of treatment and showed a decrease in HAMD score of ≥50% at the last observation compared with when treatment started.

Statistical Analysis

We included participants who passed the PRT quality control criteria, were nonresponders to sertraline or placebo in stage 1, and completed ≥4 weeks of stage 2 treatment on bupropion (after switching from sertraline) or sertraline (after switching from placebo). Independent-samples t tests assessed whether responders and nonresponders to bupropion or sertraline differed in baseline HAMD, week 8 HAMD, and change in HAMD from baseline to week 8. Next, separate 2-way treatment (sertraline vs. bupropion) × response (responder vs. nonresponder) analyses of variance were run to evaluate pre-treatment differences in response bias, discriminability, reward sensitivity and learning rate. Significant treatment × response interactions were followed by simple-effects analyses comparing responders and nonresponders to each treatment. $p < .05$ was taken to be statistically significant unless otherwise stated. Bayesian statistical analyses were also conducted using JASP (78) to complement classical statistics. The Bayes factor (BF10) quantifies the amount of evidence in favor of the alternative hypothesis and generally (79), with $1 < BF_{10} < 3$ indicating anecdotal evidence, $3 < BF_{10} < 10$ indicating substantial evidence, $10 < BF_{10} < 30$ indicating strong evidence, $30 < BF_{10} < 100$ indicating very strong evidence, and $BF_{10} > 100$ indicating extreme evidence for the alternative hypothesis.

RESULTS

Participant Characteristics

Data from 241 participants were analyzed. A total of 87 pat-
tients had valid PRT data (84 of whom had valid MR data) and completed ≥4 weeks of stage 2 medication (Supplemental Figure S1). Of these patients, 38 were nonresponders to sertraline in stage 1 and took bupropion in stage 2, while 49 were placebo nonresponders who switched to sertraline. In addition, 38 healthy control subjects were also analyzed. The clinical and demographic characteristics are reported in Table 1. In addition, we included a replication sample of 116 patients with MDD who had valid PRT data (112 of whom had valid MR data) and completed ≥4 weeks of sertraline treatment in stage 1 (Supplemental Table S2). These participants served as an independent group to verify our stage 2 sertraline findings.
Table 1. Clinical and Demographic Characteristics of Stage 2 Sample

<table>
<thead>
<tr>
<th>Variable</th>
<th>Healthy Subjects (n = 38)</th>
<th>MDD Patients (n = 87)</th>
<th>Bupropion Responders (n = 16)</th>
<th>Nonresponders (n = 22)</th>
<th>p</th>
<th>Sertraline Responders (n = 25)</th>
<th>Nonresponders (n = 24)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, Years, Mean (SD)</td>
<td>37.4 (14.9)</td>
<td>39.9 (13.8)</td>
<td>37.0 (14.6)</td>
<td>39.4 (15.1)</td>
<td>.63</td>
<td>42.1 (11.9)</td>
<td>40.0 (14.5)</td>
<td>.57</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>23 (60.5%)</td>
<td>56 (64.4%)</td>
<td>10 (62.5%)</td>
<td>17 (77.3%)</td>
<td>.32</td>
<td>16 (64.0%)</td>
<td>13 (54.2%)</td>
<td>.48</td>
</tr>
<tr>
<td>Education, Years, Mean (SD)</td>
<td>15.6 (4.5)</td>
<td>15.2 (2.6)</td>
<td>15.6 (2.0)</td>
<td>14.6 (3.0)</td>
<td>.28</td>
<td>15.4 (2.6)</td>
<td>15.4 (2.5)</td>
<td>.93</td>
</tr>
<tr>
<td>Age at MDD Onset, Years, Mean (SD)</td>
<td>–</td>
<td>16.1 (5.5)</td>
<td>14.1 (3.6)</td>
<td>16.3 (6.8)</td>
<td>.26</td>
<td>16.4 (5.5)</td>
<td>17.0 (5.2)</td>
<td>.70</td>
</tr>
<tr>
<td>Length of Current MDE, Median, Months</td>
<td>–</td>
<td>24</td>
<td>27</td>
<td>36</td>
<td>–</td>
<td>18</td>
<td>27</td>
<td>–</td>
</tr>
<tr>
<td>Prior MDEs, Median No.</td>
<td>–</td>
<td>–</td>
<td>5</td>
<td>5</td>
<td>6.5</td>
<td>6</td>
<td>3.5</td>
<td>–</td>
</tr>
<tr>
<td>Baseline HAMD Score, Mean (SD)</td>
<td>0.7 (8.8)</td>
<td>18.7 (4.1)</td>
<td>18.5 (4.0)</td>
<td>19.2 (4.6)</td>
<td>.62</td>
<td>18.3 (4.6)</td>
<td>18.7 (3.2)</td>
<td>.74</td>
</tr>
<tr>
<td>Week 4–8 HAMD Score, Mean (SD)</td>
<td>–</td>
<td>16.7 (4.9)</td>
<td>17.1 (5.1)</td>
<td>16.7 (5.0)</td>
<td>.79</td>
<td>16.9 (5.3)</td>
<td>16.2 (4.2)</td>
<td>.61</td>
</tr>
<tr>
<td>Week 12–16 HAMD Score, Mean (SD)</td>
<td>–</td>
<td>10.1 (6.2)</td>
<td>5.9 (3.3)</td>
<td>13.9 (4.5)</td>
<td>&lt;.001</td>
<td>5.8 (3.6)</td>
<td>13.9 (6.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Baseline QIDS Score, Mean (SD)</td>
<td>1.4 (1.3)</td>
<td>18.3 (2.9)</td>
<td>19.6 (3.2)</td>
<td>18.3 (3.1)</td>
<td>.22</td>
<td>17.7 (2.5)</td>
<td>18.1 (3.0)</td>
<td>.61</td>
</tr>
</tbody>
</table>

*p Values are comparisons between responders and nonresponders.

HAMD, 17-item Hamilton Rating Scale for Depression; MDD, major depressive disorder; MDE, major depressive episode; QIDS, Quick Inventory of Depressive Symptomatology.

a t test.

b t2 test.

*If patients completed at least 4 weeks of treatment but not the full 8-week course, we considered their last HAMD observation as the outcome of the treatment.

Pretreatment Response Bias Differentiated Responders to Bupropion After Failing Sertraline From Nonresponders Resistant to Both Classes of Medication

To investigate whether PRT response bias could differentiate between response to bupropion (after switching from sertraline) and response to sertraline (after previous nonresponse to placebo) in stage 2, we conducted a treatment (sertraline vs. bupropion) × response (responders vs. nonresponders) analysis of variance. Notably, the only significant effect to emerge was the treatment × response interaction ($F_{1,83} = 7.21, p < .01, \eta^2_p = .080, BF_{10} = 5.27$) (Figure 1A). Follow-up simple-effects tests revealed that eventual stage 2 bupropion responders had larger (rather than lower, as originally hypothesized) pretreatment response bias than nonresponders ($p < .01, d = 0.90, BF_{10} = 15.57$). Conversely, there was no difference between sertraline responders and nonresponders ($p > .05, d = 0.26, BF_{10} = 0.38$). We conducted a separate analysis including site as a covariate and obtained similar results. Control analyses using discriminability also showed no significant interaction or main effects, suggesting that findings were specific to response bias (see Supplemental Results). Moreover, bupropion responders exhibited comparable response bias scores as healthy control subjects ($t_{50} = 1.17, p > .05, d = 0.35, BF_{10} = 0.51$), but nonresponders had significantly lower response bias than healthy counterparts ($t_{50} = -2.77, p < .01, d = 0.74, BF_{10} = 5.90$). This suggests that individuals who eventually responded favorably to bupropion had normal reward responsiveness, whereas nonresponders did not.

Importantly, for each treatment, responders and nonresponders to bupropion or sertraline did not differ in HAMD at baseline (bupropion: $t_{24} = 0.51, p > .05, d = 0.17, BF_{10} = 0.35$; sertraline: $t_{36} = 0.34, p > .05, d = 0.10, BF_{10} = 0.30$) or week 8 (bupropion: $t_{36} = 0.27, p > .05, d = 0.09, BF_{10} = 0.33$; sertraline: $t_{36} = -0.52, p > .05, d = 0.15, BF_{10} = 0.32$) or in change in HAMD from baseline to week 8 (bupropion: $t_{36} = -0.41, p > .05, d = 0.13, BF_{10} = 0.34$; sertraline: $t_{36} = -0.63, p > .05, d = 0.18, BF_{10} = 0.34$) (Table 1). Thus, PRT findings were not influenced by differences in symptom severity at baseline or in stage 1, and baseline response bias distinguished stage 2 responders and nonresponders 12 to 16 weeks later.

Computational Modeling Revealed That Bupropion Responders Had Greater Reward Sensitivity, but Not Greater Learning Rate, Than Nonresponders

An analysis of variance revealed a significant treatment × response interaction for reward sensitivity ($F_{1,83} = 7.12, p < .05, \eta^2_p = .079, BF_{10} = 5.15$) (Figure 1B). Follow-up tests showed that eventual bupropion responders were more sensitive to rewards at the pretreatment session than nonresponders ($p < .05, d = 0.87, BF_{10} = 7.48$), whereas stage 2 sertraline responders and nonresponders did not differ ($p > .05, d = 0.29, BF_{10} = 0.36$). We also found that reward sensitivity for bupropion responders was similar to that for healthy volunteers ($t_{50} = 0.82, p > .05, d = 0.26, BF_{10} = 0.39$), but reward sensitivity for nonresponders was significantly lower than that for control subjects ($t_{50} = -2.14, p < .05, d = 0.59, BF_{10} = 1.75$). This suggests that patients who responded better to bupropion showed normative reward sensitivity. When
Reward Biomarkers of Response to Bupropion

Figure 1. Comparison of response bias (A), reward sensitivity (B), and learning rate (C) for the probabilistic reward task at baseline. Bupropion (BUP) responders in phase 2 have significantly greater baseline (pretreatment) response bias and reward sensitivity, but not learning rate, compared with nonresponders. On the other hand, there was no difference on these metrics between responders and nonresponders to sertraline (SER). Note that the reward sensitivity and learning rate parameters have been transformed to prevent issues with non-Gaussianity, *p < .05, **p < .01.

Considering learning rate, the treatment × response effect was not significant (F(1,83) = 0.55, p > .05, ɳ² = 0.007, BF₁₀ = 0.38) (Figure 1C). Results remained significant when including site as a covariate (see Supplemental Results). Thus, the difference in response bias between bupropion responders and nonresponders was likely driven by variations in reward sensitivity rather than learning rate.

Higher RSFC Between NACC and rACC Was Associated With Better Response to Bupropion

Whole-brain analyses showed a significant interaction between medication type and medication response in RSFC between the bilateral NACC and a region of the rACC (cluster peak at Montreal Neurological Institute coordinates x = −6, y = 30, z = 12, maximum t = 5.76, k = 170 voxels, clustering threshold p < .001, false discovery rate p < .05) (Figure 2). Post hoc analyses indicated that among those assigned to bupropion, patients with higher NACC–rACC RSFC showed better treatment response than those with lower NACC–rACC RSFC (t₁₁₄ = 4.48, p < .01, d = 1.21, BF₁₀ > 100). There was also a significant positive correlation between reward sensitivity and NACC–rACC RSFC (r = .22, p < .05), indicating that individuals with greater frontostriatal connectivity were more sensitive to rewards.

Compared with healthy control subjects, bupropion responders had significantly larger NACC–rACC RSFC (t₅₁ = 3.64, p < .001, d = 1.05, BF₁₀ = 44.25), while that for nonresponders was lower at a trend level (t₅₀ = −1.84, p = .07, d = 0.51, BF₁₀ = 1.10). This suggests that patients who responded better to bupropion exhibited elevated NACC–rACC RSFC. Conversely, among individuals randomized to sertraline, patients with higher NACC–rACC RSFC showed poorer treatment response than those with lower NACC–rACC RSFC (t₄₈ = 4.48, p < .01, d = 0.93, BF₁₀ = 37.47). Sertraline responders also had lower NACC–rACC RSFC than healthy control subjects (t₆₀ = −3.70, p < .001, d = 0.97, BF₁₀ = 58.92), but there was no difference between nonresponders and control subjects (t₆₈ = 0.83, p > .05, d = 0.21, BF₁₀ = 0.36).

Of note, separate voxelwise analyses performed within each medication group converged with the full-group results and suggested that NACC–rACC RSFC was especially related to treatment response in the bupropion group. Within the bupropion group, those who responded to treatment showed higher NACC–rACC RSFC, and no other significant effects were observed across the brain; however, within the sertraline group, there were no significant differences in NACC RSFC across the brain (Figure 3).

Findings for Sertraline Were Replicated in an Independent Sample

Unique individuals were treated with sertraline in stage 1 versus stage 2. Hence, patients randomized to sertraline in stage 1 could serve as an independent sample to replicate results. Consistent with stage 2 findings, responders and nonresponders to sertraline in stage 1 did not differ in PRT response bias (t₁₁₄ = 0.24, p > .05, d = 0.04, BF₁₀ = 0.23), reward sensitivity (t₁₁₄ = −0.15, p > .05, d = 0.03, BF₁₀ = 0.20), or learning rate (t₁₁₄ = −0.58, p > .05, d = 0.11, BF₁₀ = 0.27). There was also no statistical difference in NACC–rACC RSFC between stage 1 responders and nonresponders to sertraline (t₁₁₀ = 1.53, p > .05, d = 0.29, BF₁₀ = 0.57).

No Difference in Dosage of Sertraline Received in Stage 1 by Eventual Bupropion Responders and Nonresponders

The mechanism of action of bupropion is postulated to be primarily related to the inhibition of the reuptake of both dopamine and norepinephrine (80). Conversely, sertraline typically inhibits the neuronal reuptake of serotonin—although it also shows relatively high affinity for the dopamine transporter. As such, it has been suggested that sertraline might inhibit the reuptake of dopamine, particularly at high doses of 200 mg and above (83). When evaluating sertraline doses in Stage 1 by patients who went on to receive bupropion in stage 2, we found that the average dose was well below 200 mg (mean = 118.3 mg, SD = 26.7, range = 57.1–155.2). Hence, it is
difficult to disentangle the contributions of dopamine and noradrenaline to the efficacy of bupropion.

**DISCUSSION**

Treatment for MDD is challenging and often proceeds with SSRIs as first-line antidepressants (38). Unfortunately, treatment selection is not informed by biomarkers, response rates are modest, and patients with depression who do not benefit from an adequate trial of SSRIs are typically switched to non-SSRI agents (38–41). To the best of our knowledge, this is the first study to investigate behavioral and neural factors associated with response to the atypical antidepressant bupropion (which is assumed to increase dopaminergic and noradrenergic transmission) following a failure to respond to the serotonergic-based antidepressant sertraline.

Notably, we found that greater reward sensitivity and higher RSFC between the NACC and rACC distinguished bupropion responders, who previously failed to respond to sertraline, from nonresponders resistant to both classes of medication. Moreover, patients who responded better to bupropion had comparable reward sensitivity and potentiated NACC–rACC connectivity relative to healthy control subjects. In contrast, both reward sensitivity and NACC–rACC connectivity in bupropion nonresponders were lower than those in healthy volunteers. Our results cannot provide a mechanistic explanation, but we speculate that these might reflect compensatory mechanisms in depression, where elevated frontostriatal network functional connectivity is needed to respond normatively to reward.

**Figure 2.** Baseline resting-state functional connectivity (RSFC) of bilateral nucleus accumbens (NACC) is associated with differential response to bupropion (BUP) compared with sertraline (SER). (A) Shown is the seed region of interest (ROI) in bilateral NACC, anatomically defined using the Automated Anatomical Labeling atlas. (B) The interaction between antidepressant type and response to treatment was associated with RSFC (Fisher’s z-transformed Pearson’s correlations across the full duration of the resting scan) between bilateral NACC and a region of rostral anterior cingulate cortex (rACC). (C) Patients randomized to bupropion for stage 2 who responded to treatment showed higher NACC–rACC RSFC before the onset of stage 1 than patients who failed to respond to bupropion, and this pattern also emerged in separate voxelwise analysis within the bupropion group (Figure 3). Patients randomized to sertraline who responded to treatment showed lower NACC–rACC RSFC than sertraline nonresponders, but this effect failed to emerge in separate voxelwise analyses within the sertraline group (Figure 3). Voxelwise analyses thresholded at peak $p < .001$ (two-sided), false discovery rate–corrected $p < .05$. **$p < .01$.**

**Figure 3.** Voxelwise resting-state functional connectivity (RSFC) of bilateral nucleus accumbens (NACC) of responders vs. nonresponders within treatment groups. (A) Shown is the seed region of interest (ROI) in bilateral NACC, anatomically defined using the Automated Anatomical Labeling atlas. (B) Patients randomized to bupropion (BUP) who responded to treatment showed higher NACC–rACC RSFC than patients who failed to respond to BUP. (C) Among patients randomized to sertraline (SER), there was no difference in NACC RSFC between those who responded to treatment and those who failed to respond to treatment. Voxelwise static analyses thresholded at peak $p < .005$ (two-sided), false discovery rate–corrected $p < .05$. MNI, Montreal Neurological Institute; rACC, rostral anterior cingulate cortex.
Future studies are needed to test this hypothesis. Our findings also suggest that depressed individuals with more normative reward behavior and potentiated brain reward system responded better to bupropion after failing an 8-week treatment with sertraline. In contrast, we found that these reward markers were not associated with response to sertraline in stage 2 (after previous nonresponse to placebo) and replicated this null finding in an independent sample of patients randomized to sertraline in stage 1. These findings contrast with our original hypotheses, which were originally derived from the assumptions that 1) SSRIs poorly address anhedonic phenotypes (81) and 2) patients with behavioral and neural markers indexing blunted reward processing would disproportionately benefit from pharmacological treatment assumed to increase dopaminergic (and noradrenergic) transmission (62,63,82).

Although unexpected, our results are in line with earlier suggestions that patients with a subtype of depression characterized by preserved reward sensitivity may preferentially improve with dopaminergic pharmacotherapy (83) and recent reports that patients with MDD with more normative reward-related brain responses benefited the most from behavioral activation treatment (84,85). Moreover, a recent study found that depressed individuals with higher baseline response bias responded more favorably to treatment by pramipexole, a selective dopamine agonist (86,87). However, this latter study did not include placebo or nondopaminergic control. The current study demonstrated that better reward sensitivity and more positive RSFC among regions putatively involved in reward processing were associated with superior response to treatment by bupropion, one of the few antidepressants that prevent the reuptake of dopamine. In contrast, these effects were not found for the common SSRI sertraline.

Current results might have significant clinical implications. Although extant guidelines recommend SSRIs when starting treatment for MDD (38)—with sertraline being the most widely prescribed antidepressant in the United States (89) and Japan (89)—only 50% of patients benefit from them. A failure to respond to first-line antidepressants requires consideration of various second-line treatments, which include switching to a different medication, augmenting with a nonantidepressant drug, dose escalation, and a combination with a different antidepressant (38). However, there is no clear evidence for a particular strategy’s being superior (40,41,90–101), and second-line treatment guidelines are needed (102). Although further scrutiny is required, our results suggest that laboratory-based paradigms such as the PRT and/or imaging might be useful in informing whether norepinephrine and dopamine reuptake inhibitors could be prescribed if first-line SSRIs are not beneficial. Individuals likely to be resistant to norepinephrine and dopamine reuptake inhibitors could be recommended alternative strategies, including augmentation, psychotherapy, and neurostimulation. Hence, a prospective replication based on these biomarkers could advance clinical care.

Limitations of this work should be acknowledged. First, although the sample size for stage 1 was large (N = 296), that for stage 2 was more modest with n = 38 bupropion patients (16 responders vs. 22 nonresponders) and n = 49 sertraline patients (25 responders vs. 24 nonresponders). Nevertheless, this is the first study to examine reward biomarkers of second-line antidepressant response and thus will be valuable in guiding future studies. Second, the EMBARC trial adopted relatively strict inclusion criteria to minimize clinical heterogeneity. Hence, it is unclear whether findings will generalize to other depressed samples such as those with psychotic features or comorbid substance abuse. Third, our results are not sufficient to provide any mechanistic explanation for why patients with intact reward processing systems respond more favorably to bupropion than those with impaired reward processing systems. Future, more mechanistic studies should investigate this.

Fourth, we have shown that reward sensitivity and frontostriatal connectivity distinguished between subjects who responded to bupropion but had failed to benefit from sertraline and nonresponders resistant to both classes of medication. However, it remains to be investigated whether these reward markers might also differentiate responders to second-line treatment by placebo, given that nonresponders to sertraline in stage 1 of the EMBARC trial all were given bupropion rather than being randomized to bupropion or placebo. In other words, owing to the lack of placebo control subjects for the active treatments in stage 2, the specific secondary treatment effect of bupropion cannot be determined. This should be noted when interpreting our findings because of the considerable placebo response rate observed in stage 1. Nevertheless, the results of our study might still be useful in informing choice of second-line antidepressant when primary SSRI treatments fail, given that placebos are not prescribed in practice. Fifth, patients who received bupropion in stage 2 took sertraline in stage 1, while those in the sertraline group had previously been given placebo. While we confirmed that responders and nonresponders to secondary treatment with bupropion or sertraline did not differ in depressive symptomatology at baseline, as well as during and after stage 1, it is still possible that the baseline states prior to stages 1 and 2 may have been different. Sixth, unlike previous investigations such as the International Study to Predict Optimized Treatment in Depression (iSPOT-D) (103), measures in EMBARC were not collected posttreatment. Hence, it is unknown whether reward sensitivity and frontostriatal connectivity will change with treatment to bupropion as a function of response.

Conclusions

Using a multimodal approach, the current study showed that behavioral and neural markers of reward processing—specifically, computationally derived reward sensitivity and NACC–rACC connectivity—distinguished depressed individuals likely to benefit from a dopaminergic medication, following failure on SSRIs, and patients expected to be resistant to both classes of antidepressants. With further scrutiny, these findings could have important implications for clinical care.

Acknowledgments and Disclosures

The EMBARC study was supported by the National Institute of Mental Health (NIMH) under Grant Nos. U01MH092221 (to MHT) and U01MH092250 (to PM, RP, and MW). Y-SA and DAP were supported by the A*STAR National Science Scholarship and Grant No. R37 MH068376, respectively. This work was supported by the EMBARC National Coordinating Center at UT Southwestern Medical Center (coordinating principal
investigator: MHT) and the Data Center at Columbia and Stony Brook Universities.

The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).

We are grateful to Daniel G. Dillon for his helpful comments on the manuscript.

The authors report the following financial disclosures, in the last 3 years (unless otherwise noted), for activities unrelated to the current research. MHT reports the following lifetime disclosures: research support from Agency for Healthcare Research and Quality, Cyberonics Inc., National Alliance for Research in Schizophrenia and Depression (NARSAD), NIMH, National Institute on Drug Abuse (NIDA), National Institute of Diabetes and Digestive and Kidney Diseases, and Johnson & Johnson; consulting and speaker fees from Abbott Laboratories Inc., Akzo (Organon Pharmaceuticals Inc.), Allergan Sales, Akermes, AstraZeneca, Axon Advisors, Brintellix, Bristol-Myers Squibb, Cephalon Inc., Cerecor, Eis Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals Inc., Forest Pharmaceuticals, GlaxoSmithKline Health Research Associates, Johnson & Johnson, Lundbeck, MedAvante Medscape, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America Inc., MSI Methylation Sciences Inc., Nestle Health Science-Pamlab Inc., Naurex, Neuronetics, One Carbon Therapeutics Ltd., Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals Inc., Pfizer Inc., PggHealth, Phoenix Marketing Solutions, Raxahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. MF reports the following: research support from Acadia Pharmaceuticals, Allergan, Alkermes, Inc., Aplynx, Avanir Pharmaceuticals Inc., Assome, Benckiser Pharmaceuticals Inc., BioClinica, Inc., Biogen, Biohaven, Cambridge Science Corporation, Cerecor, Gate Neurosciences Inc., GenOmind, LLC, Gentelon, LLC, Happify, Johnson & Johnson, Lundbeck Inc., Marinus Pharmaceuticals, Methylation Sciences Inc., Millennium Pharmaceuticals, Inc. Minerva Neurosciences, Neurosalem, NeuroRX Inc., Novartis, Otsuka, Pfizer, Premiere Research International, Relmada Therapeutics Inc., Reclont, Shenox Pharmaceuticals, Stanley Medical Research Institute, Taisho, Takeda, Vistagen, NIDA, NIH, NIMH, and PCORI; equity holdings in Compellis, Psy Therapeutics; patents for sequential parallel comparison design, licensed by MGH to Pharmaceutical Product Development, LLC (US_7844019, US_7647235, US_7983936, US_8145504, US_8145505); a patent application for a combination of ketamine plus scopolamine in MDD, licensed by MGH to Biohaven; patents for pharmacogenomics of depression treatment with folate (US_2006/0010940, US_2006/0010941); copyright for the MGH Cognitive & Physical Functioning Questionnaire, Sexual Functioning Inventory, Antidepressant Treatment Response Questionnaire, Discontinuation-Emergent Signs & Symptoms, Symptoms of Depression Questionnaire, and SAFER; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte. Ltd. MLP reports consulting fees from Sunovion Pharmaceuticals. MW reports funding from NIMH, NARSAD, Sackler Foundation, and the Templeton Foundation; royalties from Oxford University Press, Perseus Press, American Psychiatric Association Press, and MultiHealth Systems. MAO reports funding from NIMH; royalties for commercial use of the Columbia Suicide Severity Rating Scale; her family owns stock in Bristol-Myers Squibb. MGM reports funding from NIMH; consulting fees from Janssen Pharmaceuticals and Otsuka Pharmaceuticals. TD reports funding from NIH, NIMH, Patient-Centered Outcomes Research Institute (PCORI), NARSAD, Tourette Syndrome Association, International OCD Foundation, Tufts University, Depression and Bipolar Alternative Treatment Foundation, Otsuka Pharmaceuticals, Cogito Inc., Sunovion, and Assurex Pharmaceuticals; honoraria, consultation fees, and/or royalties from MGH Psychiatry Academy, BrainCells Inc., Cintara, Systems Research and Applications Corporation, Boston University, Categorical Agency for Health Technology Assessment and Research, National Association of Social Workers Massachusetts, Massachusetts Medical Society, Tufts University, NIDA, NIMH, Oxford University Press, and Guilford Press; he has also participated in research funded by Assurex, Defense

Advanced Research Projects Agency, NIH, NIMH, National Institute on Aging, Agency for Healthcare Research and Quality, PCORI, Janssen Pharmaceuticals, Forest Research Institute, Shire Development, Medtronic, Cyberonics, NorthStar, Takeda, and Sunovion. DAP: funding from NIMH, Brain and Behavior Research Foundation, Dana Foundation, and Millennium Pharmaceuticals; consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compaq Pathway, Posit Science, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Akermes; he has a financial interest in BlackThorn Therapeutics, which has licensed the copyright to the probabilistic reward task through Harvard University; his interests were reviewed and are managed by McLean Hospital and Partners HealthCare in accordance with their conflict of interest policies. The other authors report no biomedical financial interests or potential conflicts of interest.

ClinicalTrials.gov: Establishing Moderators and Biosignatures of Anti-depressant Response for Clinical Care for Depression (EMBARC); https://clinicaltrials.gov/ct2/show/NCT01407094; NCT01407094.

ARTICLE INFORMATION

From the Department of Psychiatry (Y-SA, CAW, MF, DAP), Harvard Medical School, and Department of Psychiatry (TD, MF), Massachusetts General Hospital, Boston, and Center for Depression, Anxiety and Stress Research (Y-SA, CAW, DAP), McLean Hospital, Belmont, Massachusetts; Department of Psychology and Neuroscience (RK), University of Colorado Boulder, Boulder, Colorado; Department of Psychiatry (JA), University of Texas at Austin, Dell Medical School, Austin, and Department of Psychiatry (TC, CM, CHCF, MHT), University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Psychiatry (MLP, HWC), University of Pittsburgh, Pittsburgh, and Department of Psychiatry (MAO), University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Psychiatry (RP), Stony Brook University, Stony Brook, and New York State Psychiatric Institute and Department of Psychiatry (PM, MW, PA, GB), Columbia University Vagelos College of Physicians and Surgeons, New York, New York; and Department of Psychiatry (PD, MGGM), University of Michigan, Ann Arbor, Michigan.

Address correspondence to Diego A. Pizzagalli, Ph.D., Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill St., Room 233C, Belmont, MA 02478; E-mail: dapo@mclean.harvard.edu.

Received Dec 2, 2019; revised Mar 24, 2020; accepted Apr 13, 2020. Supplementary material cited in this article is available online at https://doi.org/10.1016/j.biopsych.2020.04.009.

REFERENCES

Reward Biomarkers of Response to Bupropion

Reward Biomarkers of Response to Bupropion


